(S)-4-((S)-2-acetamido-3-phenylpropanamido)-5-((S)-1-((3S,6R,11R,14S,17S,20S,23S,26S,31aS)-3,14-bis((1H-imidazol-5-yl)methyl)-6-((2R,3R)-1-((R)-1-((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylamino)-5-guanidino-1-oxopentan-2-ylamino)-3-hydroxy-1-oxobutan-2-ylcarbamoyl)-20-sec-butyl-17-(4-hydroxybenzyl)-26-isobutyl-1,4,12,15,18,21,24,27-octaoxo-23-(4-(2-(2-oxo-2-(4-(3-oxo-3-(2-oxoazetidin-1-yl)propyl)phenylamino)ethoxy)acetamido)butyl)octacosahydro-1H-pyrrolo[2,1-j][1,2,5,8,11,14,17,20,23,26]dithiaoctaazacyclononacosin-11-ylamino)-3-methyl-1-oxobutan-2-ylamino)-5-oxopentanoic acid

ID: ALA1689480

Chembl Id: CHEMBL1689480

Max Phase: Preclinical

Molecular Formula: C106H146N26O26S2

Molecular Weight: 2264.62

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)C(C)C)CSSC[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccc(O)cc2)C(N)=O)[C@@H](C)O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNC(=O)COCC(=O)Nc2ccc(CCC(=O)N3CCC3=O)cc2)NC1=O

Standard InChI:  InChI=1S/C106H146N26O26S2/c1-9-59(6)89-103(155)119-71(19-13-14-39-112-83(137)51-158-52-84(138)117-66-29-22-62(23-30-66)28-36-85(139)132-42-38-86(132)140)93(145)125-79(43-57(2)3)105(157)131-41-16-21-82(131)101(153)124-78(48-68-50-111-56-115-68)97(149)126-81(100(152)130-90(60(7)133)104(156)120-72(20-15-40-113-106(108)109)92(144)121-74(91(107)143)44-64-24-31-69(135)32-25-64)54-160-159-53-80(99(151)123-77(47-67-49-110-55-114-67)96(148)122-76(98(150)129-89)46-65-26-33-70(136)34-27-65)127-102(154)88(58(4)5)128-94(146)73(35-37-87(141)142)118-95(147)75(116-61(8)134)45-63-17-11-10-12-18-63/h10-12,17-18,22-27,29-34,49-50,55-60,71-82,88-90,133,135-136H,9,13-16,19-21,28,35-48,51-54H2,1-8H3,(H2,107,143)(H,110,114)(H,111,115)(H,112,137)(H,116,134)(H,117,138)(H,118,147)(H,119,155)(H,120,156)(H,121,144)(H,122,148)(H,123,151)(H,124,153)(H,125,145)(H,126,149)(H,127,154)(H,128,146)(H,129,150)(H,130,152)(H,141,142)(H4,108,109,113)/t59-,60+,71-,72+,73-,74+,75-,76-,77-,78-,79-,80-,81-,82-,88-,89-,90+/m0/s1

Standard InChI Key:  PSHTWLDWKUGJNS-ZCUGKWHYSA-N

Alternative Forms

  1. Parent:

    ALA1689480

    ---

Associated Targets(non-human)

Pgf Placenta growth factor (17 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Serum (598 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 2264.62Molecular Weight (Monoisotopic): 2263.0343AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Bower KE, Lam SN, Oates BD, Del Rosario JR, Corner E, Osothprarop TF, Kinhikar AG, Hoye JA, Preston RR, Murphy RE, Campbell LA, Huang H, Jimenez J, Cao X, Chen G, Ainekulu ZW, Datt AB, Levin NJ, Doppalapudi VR, Pirie-Shepherd SR, Bradshaw C, Woodnutt G, Lappe RW..  (2011)  Evolution of potent and stable placental-growth-factor-1-targeting CovX-bodies from phage display peptide discovery.,  54  (5): [PMID:21280651] [10.1021/jm101226k]

Source